Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome

Szejko, Natalia; Saramak, Kamila; Lombroso, Adam; Müller-Vahl, Kirsten

doi:10.5603/pjnns.a2021.0081

Cited by 17 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There also is a growing body of evidence supporting Cannabis and cannabinoids for treating patients suffering from drug addiction, 9 multiple sclerosis, 10 anorexia nervosa, 11 epilepsy 12 and Tourette syndrome. 13 We state here, however, that maternal use of Cannabis during pregnancy has been associated with higher incidence of autism spectrum disorder in the offspring, 14 an important point given the common perception that it is safe to use Cannabis during pregnancy. 15 Aside from clinical use, THC also is widely used globally for its psychoactive effects.…”

mentioning

confidence: 79%

Towards dsRNA‐integrated protection of medical Cannabis crops: considering human safety, recent‐ and developing RNAi methods, and research inroads

Willow

Silva

Taning

et al. 2022

Pest Management Science

View full text Add to dashboard Cite

Owing to the expanding industry of medical Cannabis, we discuss recent milestones in RNA interference (RNAi)-based crop protection research and development that are transferable to medical Cannabis cultivation. Recent and prospective increases in pest pressure in both indoor and outdoor Cannabis production systems, and the need for effective nonchemical pest control technologies (particularly crucial in the context of cultivating plants for medical purposes), are discussed. We support the idea that developing RNAi tactics towards protection of medical Cannabis could play a major role in maximizing success in this continuously expanding industry. However, there remain critical knowledge gaps, especially with regard to RNA pesticide biosafety from a human toxicological viewpoint, as a result of the medical context of Cannabis product use. Furthermore, efforts are needed to optimize transformation and micropropagation of Cannabis plants, examine cutting edge RNAi techniques for various Cannabis-pest scenarios, and investigate the combined application of RNAi-and biological control tactics in medical Cannabis cultivation.

show abstract

mentioning

confidence: 79%

Towards dsRNA‐integrated protection of medical Cannabis crops: considering human safety, recent‐ and developing RNAi methods, and research inroads

Willow

Silva

Taning

et al. 2022

Pest Management Science

View full text Add to dashboard Cite

show abstract

“…Lastly, cannabinoid receptors are also a prime target of the exogenous cannabinoid D9-tetrahydrocannabinol (THC), the psychotropic component of cannabis. In this respect, a putatively beneficial role of cannabis in TD treatment comes from anecdotal evidence of patients reporting improvement in their tics after using cannabis [ 155 ] as well as some case studies and clinical trials (summarized in [ 156 , 157 ]). That being said, as most of these studies provide only low level of evidence for a beneficial effect, the European and American authorities currently only recommend cannabis use for (adult) treatment-resistant TD cases in which established therapy did not alleviate symptoms [ 10 , 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

Molecular Landscape of Tourette’s Disorder

Widomska

Witte

Buitelaar

et al. 2023

IJMS

View full text Add to dashboard Cite

Tourette’s disorder (TD) is a highly heritable childhood-onset neurodevelopmental disorder and is caused by a complex interplay of multiple genetic and environmental factors. Yet, the molecular mechanisms underlying the disorder remain largely elusive. In this study, we used the available omics data to compile a list of TD candidate genes, and we subsequently conducted tissue/cell type specificity and functional enrichment analyses of this list. Using genomic data, we also investigated genetic sharing between TD and blood and cerebrospinal fluid (CSF) metabolite levels. Lastly, we built a molecular landscape of TD through integrating the results from these analyses with an extensive literature search to identify the interactions between the TD candidate genes/proteins and metabolites. We found evidence for an enriched expression of the TD candidate genes in four brain regions and the pituitary. The functional enrichment analyses implicated two pathways (‘cAMP-mediated signaling’ and ‘Endocannabinoid Neuronal Synapse Pathway’) and multiple biological functions related to brain development and synaptic transmission in TD etiology. Furthermore, we found genetic sharing between TD and the blood and CSF levels of 39 metabolites. The landscape of TD not only provides insights into the (altered) molecular processes that underlie the disease but, through the identification of potential drug targets (such as FLT3, NAALAD2, CX3CL1-CX3CR1, OPRM1, and HRH2), it also yields clues for developing novel TD treatments.

show abstract

“…An ongoing RCT called CANNA-TICS is assessing whether treatment with cannabis extract nabiximols (Sativex®) is superior to placebo in patients with chronic tic disorders [ 23 ]. In addition to these RCTs, retrospective data analysis and case series [ 24 – 27 ] along with multiple case reports [ 28 – 37 ] have been published and summarized in a recent review of the literature by Szejko et al [ 38 ], suggesting that cannabis-based medicine (CBM) could be effective and relatively safe in suppressing tics and in the treatment of associated psychiatric comorbidities in patients with GTS. In the recent AAN guideline recommendation summary [ 9 ], cannabis-based therapies were suggested to have limited evidence to reduce tic severity, although, where regional legislation allows, physicians may consider treatment with CBM in otherwise treatment-resistant adults with clinically relevant tics (level C).…”

Section: Introductionmentioning

confidence: 99%

Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study

Anis

Zalomek

Korczyn

et al. 2022

Behavioural Neurology

View full text Add to dashboard Cite

Objectives. Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. Methods. We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and the patient. Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) content within MC product and monthly dose were titrated during the study. Following treatment initiation, patients were assessed after 4 and 12 weeks for efficacy, tolerability, and side effects. Results. Eighteen patients entered the study. Baseline Yale Global Tic Severity Scale- (YGTSS) Total (range 0-100) was 60.3 ± 17.1 . Three patients did not reach the end of follow-up period. The most common mode of administration was smoking (80%). Following twelve weeks of treatment, a significant 38% average reduction ( p = 0.002 ) of YGTSS-Total and a 20% reduction ( p = 0.043 ) of Premonitory Urge for Tic Scale (PUTS) were observed. Common side effects were dry mouth (66.7%), fatigue (53.3%), and dizziness (46.7%). Three patients suffered from psychiatric side effects including worsening of obsessive compulsive disorder (stopped treatment), panic attack, and anxiety (resolved with treatment modification). Six patients (40%) reported cognitive side effects regarding time perception, visuospatial disorientation, confusion, slow processing speed, and attention. Conclusions. MC treatment demonstrates good efficacy and tolerability in adult GTS patients. Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each. Cognitive and psychiatric side effects have to be monitored and addressed.

show abstract

Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome

Cited by 17 publications

References 55 publications

Towards dsRNA‐integrated protection of medical Cannabis crops: considering human safety, recent‐ and developing RNAi methods, and research inroads

Towards dsRNA‐integrated protection of medical Cannabis crops: considering human safety, recent‐ and developing RNAi methods, and research inroads

Molecular Landscape of Tourette’s Disorder

Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study

Contact Info

Product

Resources

About